TNFSF11 and bone metastasis: Therefore, osteoclast-targeting therapy is extensively used for osteolytic bone metastasis in the clinic, including denosumab, a RANKL antibody that blocks osteoclast differentiation and resorption, and bisphosphonate, a potent small-molecule inhibitor of osteoclast-mediated bone resorption (7, 8).